- Edwards Lifesciences (NYSE:EW) has prevailed in an Inter Partes Review of Boston Scientific's (BSX) U.S. Patent No. 8,992,608 covering its transcatheter heart valve. The USPTO ruled that the all claims under the patent are invalid.
- BSX filed infringement litigation in 2016. Edwards returned the favor and filed infringement litigation against BSX related to three patents protecting its transcatheter valve. A ruling is expected later this year.
Edwards Lifesciences prevails in challenge to Boston Sci valve patent
Recommended For You
About EW Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EW | - | - |
Edwards Lifesciences Corporation |